J&J reportedly in talks to reduce offer for Elan stock

Johnson & Johnson is in talks to reduce by at least $100 million its offer to purchase an 18.4% stake in Elan, after a court ruled that part of the deal violates Elan's drug partnership with Biogen Idec, sources said. J&J and Elan declined to comment on the negotiations, which would change J&J's $1 billion cash bid but keep intact its $500 million investment in Elan's drugs.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN